Medical Management Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong 250117, China.
Department of Aviation Medicine, Naval Medical Institute, Second Military Medical University, Shanghai 200433, China.
Exp Biol Med (Maywood). 2020 May;245(9):823-834. doi: 10.1177/1535370220918193. Epub 2020 Apr 8.
There are currently approximately 425 million diabetic patients worldwide, of which approximately 90% of patients with diabetes suffer from neuropathy. Diabetic neuropathic pain (DNP) is a common complication of diabetic neuropathy. Nearly half of the patients hospitalized with diabetes have pain symptoms or symptoms related to neurological injury, and the incidence increases with age and diabetic duration. Anti-DNP analgesics have either limited therapeutic effects or serious side effects or lack of clinical trials, which has limited their application. Physiopathological mechanisms and treatment of DNP remain a significant challenge. The present confirmed that inhalation of HS may attenuate the diabetic neuropathic pain through NO/cGMP/PKG pathway and μ-opioid receptor. It provides us the animal study foundation for the application of HS on the treatment of DNP and clarifies some target molecules in the pain modulation of DNP.
目前全球约有 4.25 亿糖尿病患者，其中约 90%的糖尿病患者患有神经病变。糖尿病性神经病理性疼痛（DNP）是糖尿病性神经病变的常见并发症。近一半因糖尿病住院的患者有疼痛症状或与神经损伤相关的症状，且发病率随年龄和糖尿病病程的增加而增加。抗 DNP 镇痛药的治疗效果有限，或有严重的副作用，或缺乏临床试验，这限制了它们的应用。DNP 的病理生理机制和治疗仍然是一个重大挑战。本研究证实，HS 的吸入可能通过 NO/cGMP/PKG 通路和 μ-阿片受体来减轻糖尿病性神经病理性疼痛。它为我们提供了 HS 应用于 DNP 治疗的动物研究基础，并阐明了 DNP 疼痛调节中的一些靶分子。
